Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,454,822
  • Shares Outstanding, K 158,755
  • Annual Sales, $ 329,000 K
  • Annual Income, $ 23,380 K
  • EBIT $ 60 M
  • EBITDA $ 55 M
  • 60-Month Beta 2.21
  • Price/Sales 16.21
  • Price/Cash Flow 280.00
  • Price/Book 22.48

Options Overview Details

View History
  • Implied Volatility 56.79% ( -5.10%)
  • Historical Volatility 64.15%
  • IV Percentile 13%
  • IV Rank 43.15%
  • IV High 118.30% on 08/05/24
  • IV Low 10.10% on 06/10/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 7,570
  • Volume Avg (30-Day) 7,766
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 132,007
  • Open Int (30-Day) 110,101

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.27
  • Number of Estimates 6
  • High Estimate 0.59
  • Low Estimate 0.11
  • Prior Year 0.04
  • Growth Rate Est. (year over year) +575.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.68 +5.14%
on 05/13/25
46.48 -26.08%
on 05/01/25
-3.85 (-10.08%)
since 04/16/25
3-Month
28.17 +21.97%
on 02/28/25
46.48 -26.08%
on 05/01/25
+3.65 (+11.89%)
since 02/14/25
52-Week
15.16 +126.65%
on 06/10/24
46.48 -26.08%
on 05/01/25
+16.94 (+97.24%)
since 05/16/24

Most Recent Stories

More News
Why TG Therapeutics Stock Was Tumbling Today

A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics (NASDAQ: TGTX) shareholders on Monday.

TGTX : 34.36 (+2.29%)
TG Therapeutics: Q1 Earnings Snapshot

TG Therapeutics: Q1 Earnings Snapshot

TGTX : 34.36 (+2.29%)
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

TGTX : 34.36 (+2.29%)
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

TGTX : 34.36 (+2.29%)
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Shares of TG Therapeutics, Inc. TGTX have rallied 29.5% in the past three months against the industry’s decline of 11.2%.The company’s sole marketed drug Briumvi (ublituximab-xiiy) was approved by...

TGTX : 34.36 (+2.29%)
KRYS : 130.60 (+0.21%)
DTIL : 4.71 (+3.52%)
JAZZ : 108.98 (+2.74%)
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TGTX : 34.36 (+2.29%)
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TGTX : 34.36 (+2.29%)
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

TGTX : 34.36 (+2.29%)
10 Best Stocks to Invest In Right Now

The U.S. stock market is experiencing a dramatic shift and volatility thanks to a cocktail of economic policies, industry-specific downturns, and shifting investor sentiment. These macroeconomic factors...

TGTX : 34.36 (+2.29%)
PYPL : 72.18 (+0.85%)
NVDA : 135.40 (+0.42%)
AVGO : 228.61 (-1.73%)
TSLA : 349.98 (+2.09%)
AMD : 117.17 (+1.90%)
ICE : 176.25 (+0.80%)
HEI : 278.75 (+1.22%)
AMZN : 205.59 (+0.20%)
BRO : 111.77 (+1.09%)
Why TG Therapeutics Stock Was Soaring This Week

Following news of an estimates-topping fourth quarter, TG Therapeutics (NASDAQ: TGTX) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence,...

TGTX : 34.36 (+2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 35.67
2nd Resistance Point 35.09
1st Resistance Point 34.72
Last Price 34.36
1st Support Level 33.77
2nd Support Level 33.19
3rd Support Level 32.82

See More

52-Week High 46.48
Fibonacci 61.8% 34.52
Last Price 34.36
Fibonacci 50% 30.82
Fibonacci 38.2% 27.12
52-Week Low 15.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar